Stimuvax (i.e., MUC1-specific), Tecemotide (i.e., MUC1-specific), and sHER2+AS15 are notable examples of liposome-based cancer nanovaccines that have progressed through phase-II/III clinical trials to treat melanoma and NSCLC, breast cancer, and PDAC, respectively. This evidence concerns the gene MUC1 and breast carcinoma.